Market Cap | 892.20M | P/E | - | EPS this Y | 7.00% | Ern Qtrly Grth | - |
Income | -171.53M | Forward P/E | - | EPS next Y | 43.70% | 50D Avg Chg | -4.00% |
Sales | 50.83M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -18.00% |
Dividend | N/A | Price/Book | 78.95 | EPS next 5Y | - | 52W High Chg | -64.00% |
Recommedations | 2.00 | Quick Ratio | 0.18 | Shares Outstanding | 131.72M | 52W Low Chg | 109.00% |
Insider Own | 32.74% | ROA | -53.64% | Shares Float | 56.78M | Beta | 1.19 |
Inst Own | 21.08% | ROE | - | Shares Shorted/Prior | 9.32M/8.23M | Price | 6.00 |
Gross Margin | 68.24% | Profit Margin | -233.88% | Avg. Volume | 525,154 | Target Price | 5.50 |
Oper. Margin | -95.44% | Earnings Date | - | Volume | 695,494 | Change | 14.94% |
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company has a collaboration with ACEA Therapeutics to Support the Expansion of ZTlido program. Scilex Holding Company is headquartered in Palo Alto, California.
HC Wainwright & Co. | Buy | Jun 17, 24 |
Rodman & Renshaw | Buy | Jun 13, 24 |
HC Wainwright & Co. | Buy | Jun 11, 24 |
HC Wainwright & Co. | Buy | May 23, 24 |
HC Wainwright & Co. | Buy | May 3, 24 |
HC Wainwright & Co. | Buy | Dec 4, 23 |
B. Riley Securities | Buy | Oct 13, 23 |
HC Wainwright & Co. | Buy | Oct 9, 23 |